Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin Long-term Safety Study in T2DM
NCT00363844Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2006
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Ono Pharmaceutical. Primary endpoints: Safety at 52 weeks and Tolerability at 52 weeks. Started Aug 2006; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00363844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363844.